Log in or Sign up for Free to view tailored content for your specialty!
Retina/Vitreous News
Biosimilars have yet to make an impact in ophthalmology
It has been nearly 3 years since the first ranibizumab biosimilar was approved for use in the U.S.
Adoption of ophthalmic biosimilars expected to remain slow
Most of us are familiar with the different classes of eye drops.
Log in or Sign up for Free to view tailored content for your specialty!
FDA grants rare pediatric disease designation for Leber congenital amaurosis gene therapy
Opus Genetics received rare pediatric disease designation from the FDA for its ocular gene therapy designed to treat patients with a form of Leber congenital amaurosis, according to a press release.
OCT, visual acuity popular benchmarks in clinical practice guidelines for DME
A review found that OCT and visual acuity were among the most popular benchmarks in the management of diabetic macular edema in clinical practice guidelines.
VIDEO: Safety data encouraging for 4D-150 in patients with wet AMD
In this video, Donald J. D’Amico, MD, discusses data from the phase 1/2 PRISM trial of 4D-150 in patients with neovascular age-related macular degeneration.
‘Don’t give up’: Persistent treatment with faricimab shows promise for delayed responders
Patients with neovascular age-related macular degeneration who have responded poorly to anti-VEGF monotherapy may require an average of nine injections of faricimab before improvement is seen.
VIDEO: Ixo-vec may reduce need for anti-VEGF injections in wet AMD
In this video, Donald J. D’Amico, MD, discusses data from the phase 2 LUNA trial of Ixo-vec intravitreal gene therapy for neovascular age-related macular degeneration.
VIDEO: ANX007 for geographic atrophy demonstrates visual acuity, photoreceptor benefits
In this Healio Video Perspective from the ASRS meeting, Eleonora M. Lad, MD, PhD, of Duke University Medical Center discusses findings from the phase 2 ARCHER trial investigating ANX007 for geographic atrophy.
Gene therapy for X-linked retinoschisis receives rare pediatric disease designation
The FDA granted rare pediatric disease designation to ATSN-201, a gene therapy candidate for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.
Vitreoretinal fellows steadily improve peel time over course of program
Vitreoretinal surgery fellows tend to become faster at peeling over the course of their fellowship, according to a study presented at the American Society of Retina Specialists annual meeting.
-
Headline News
Obesity rates decline for first time in a decade
December 13, 20242 min read -
Headline News
FDA committee asks for more data on RSV vaccine safety in infants
December 13, 20243 min read -
Headline News
Novel GLP-1 analog injection reduced weight for Chinese adults with overweight, obesity
December 16, 20242 min read
-
Headline News
Obesity rates decline for first time in a decade
December 13, 20242 min read -
Headline News
FDA committee asks for more data on RSV vaccine safety in infants
December 13, 20243 min read -
Headline News
Novel GLP-1 analog injection reduced weight for Chinese adults with overweight, obesity
December 16, 20242 min read